Skip to content
    BVS
    Earnings call· Jun 2026(Q2 FY26)

    Bioventus Q2 FY26 earnings call BVS

    Aug 5, 2026 Source

    Executive summary

    BioVentus Q2 FY26 — Strong Performance Across Business, Strategic Review Initiated

    BioVentus delivered solid Q2 FY26 results, driven by strong performance in Pain Treatments and disciplined cost management, leading to increased earnings and significant debt reduction. The company also announced a strategic review process initiated by its Board of Directors to evaluate options, including a potential sale, to maximize shareholder value. Despite some segment-specific headwinds, management reaffirmed full-year guidance, expressing confidence in its growth drivers and operational execution.

    Highlights

    5

    • Total revenue grew 4% year-over-year to $153 million.

    • Pain Treatments revenue grew 12% year-over-year to $82 million, driven by Duralane volume gains.

    • Adjusted EBITDA increased over $1 million, with a 23% margin, expanding 20 basis points year-over-year.

    • Adjusted EPS increased 24% year-to-date compared to prior year.

    • Net leverage reduced to below 2x, with $24 million debt repaid in Q2, bringing year-to-date repayment to $46 million.

    Concerns

    4

    • Surgical Solutions revenue declined 5% year-over-year to $50 million, impacted by timing of capital placements and international orders ($2 million shift).

    • Restorative Therapies revenue declined 2% to $21 million due to a change in mix with fewer Medicare patients.

    • International revenue was lower by 1% (2% constant currency) to $19 million due to timing of distributor orders.

    • Adjusted gross margin decreased 90 basis points to 75% due to higher freight costs and product mix.

    Guidance & targets

    7
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $600 million to $610 million
    high materiality
    High
    Full-year 2026 Adjusted EPS
    $0.75 to $0.79
    high materiality
    High
    Full-year 2026 Cash from Operations
    $84 million and $89 million
    high materiality
    High
    Full-year 2026 Adjusted EBITDA Margin
    at least 20%
    medium materiality
    High
    Net Leverage
    below 1.5 times
    high materiality
    High
    Second Half Revenue Growth
    increase by over 300 basis points
    medium materiality
    High
    Second Half Cash from Operations
    approximately double
    medium materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Global Pain Treatments
    Driven by strong growth in HA from volume gains with differentiated single injection Duralane therapy and favorable customer mix. Success reflects intense focus and strategic collaboration across salesforce, corporate accounts, and pricing teams.
    Duralane volume growth: double-digitHA franchise performance: above marketPRP and PNS contributions: positive
    		$82 million12%——
    Surgical Solutions
    Impacted by challenging prior year comparison and timing of certain ultrasonics capital placements and international orders, shifting approximately $2 million of revenue into the second half. Deliberate portfolio actions were taken to prioritize higher margin profitable growth opportunities in BGS.
    Ultrasonics disposables performance: acceleratingBGS traction: significant with new large accounts and IDNs
    		$50 million-5%5%—
    Restorative Therapies
    Resulted from a change in mix, specifically with Medicare patients, in addition to a difficult comparison to the prior year. Growth is expected to resume based on current business opportunities.
    		$21 million-2%——
    International
    Primarily due to the timing of distributor orders. Fundamental growth continues to be strong, and with increased strategic focus, talent additions, and improved commercial execution, strong double-digit growth is expected in the second half and for the full year.
    Constant currency growth: -2%
    		$19 million-1%——

    Operational metrics

    9
    Adjusted EBITDA margin
    23%+20 bps YoY
    Q2 FY26

    Expanded even with increased investment.

    Adjusted EPS growth
    24%YoY
    YTD FY26

    Compared to the prior year.

    Debt repayment
    $24 million
    Q2 FY26

    Additional repayment of term loan.

    Total debt repayment
    $46 million
    YTD FY26

    Prioritizing deleveraging and repayment of term loan.

    Adjusted gross margin
    75%-90 bps YoY
    Q2 FY26

    Lower than prior year period as expected.

    Adjusted total operating expenses and R&D
    $4 millionincreased YoY
    Q2 FY26

    As the company continues to strategically invest in key growth drivers.

    Effective tax rate
    increasedYoY
    Q2 FY26

    Due to the removal of the valuation allowance; expected to be higher for the full year.

    Investments in growth drivers
    a little bit more than $13 millionhigher than H1 FY26
    H2 FY26

    Initially highlighted $13 million for the year; will be higher in the back half, with PNS receiving the majority.

    PNS market size
    $200 million
    Today

    The company is confident its differentiated technology and go-to-market strategy position it to scale this business to over $100 million.

    Industry KPIs

    9
    MetricValueDetails
    Pricing realized price—
    Procedure volume growthDouble-digit%
    FCF conversion leverage guidanceBelow 2xx
    Installed base system placements—
    Segment franchise organic growth4%%
    Consumables recurring revenue mix—
    Sales force commercial capacity build—
    Indicated addressable patient population—
    Pivotal trial clinical evidence milestones—

    Deals & partnerships

    1
    Unnamed partiesEvaluation of strategic options, including a potential sale of the company or continued standalone execution.

    The Board has formed a committee of independent directors, assisted by Evercore as financial advisor, to evaluate options following an unsolicited acquisition proposal and multiple expressions of interest.

    Risks & headwinds

    5
    Challenging prior year comparisonQ2 FY26

    Impacted Surgical Solutions (-5% YoY) and Restorative Therapies (-2% YoY).

    Timing of orders and capital placementsQ2 FY26

    Shifted approximately $2 million of revenue from Q2 to H2, impacting Surgical Solutions and International.

    Mitigation: Expected to accelerate revenue in H2 FY26.

    Product mix and higher freight costsQ2 FY26

    Led to a 90 basis point decline in adjusted gross margin to 75%.

    Change in customer mixQ2 FY26

    Specifically with fewer Medicare patients, impacting Restorative Therapies revenue (-2% YoY).

    Mitigation: Expected growth to resume based on current business opportunities.

    Increased effective tax rateQ2 FY26 and full year

    Increased compared to prior year.

    What to watch in Q3 FY26

    5

    Surgical Solutions revenue acceleration

    H2 FY26
    Current-5% YoY in Q2, 5% sequential growth
    TargetStrong acceleration in H2, including $2M shift from Q2

    Why it matters

    Critical for overall revenue growth and achieving full-year guidance.

    More importantly, we saw great traction in ultrasonics with our leading indicators from our investments, including new accounts, new users, capital placements, and accelerated sequential growth with disposables. So we're really looking forward to the second half of the year.

    Q&A highlights

    7

    Can you elaborate on the drivers of HA growth (volume vs. price) and how BioVentus and its leading competitor are both gaining share in the single-injection market?

    Rob Claypool stated that HA growth, particularly for Duralane, was led by double-digit volume growth. He attributed this to clinical differentiation, broad private payer coverage, and commercial strength, emphasizing that the company's progress in this space is primarily volume-driven.

    “our progress and growth in this space is really driven by volume growth.”

    asked by Chase Knickerbocker · answered by Robert Claypoole

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Review Initiated

    BioVentus announced that its Board of Directors has formed a committee of independent directors to evaluate a range of strategic options, including a potential sale of the company or the continued execution of its standalone plan. This decision follows the receipt of multiple expressions of interest and an unsolicited acquisition proposal. Evercore has been appointed as the financial advisor to assist the committee in maximizing shareholder value.

    02

    Durable Growth in Pain Treatments

    The Pain Treatments business delivered strong double-digit growth in Q2 FY26, primarily driven by the HA franchise, led by Duralane. This market-leading single-injection therapy continues to outperform the market, fueled by strong commercial focus, clinical differentiation, and broad private payer coverage. The significant operating profit generated from this franchise is being strategically deployed to invest in other key growth drivers.

    03

    Investments in Key Growth Drivers Yielding Traction

    BioVentus is increasing investments in platelet-rich plasma (PRP), peripheral nerve stimulation (PNS), ultrasonics, and international markets. These investments include expanding commercial teams, raising awareness, and enhancing physician training. Early indicators show positive traction, such as accelerating capital placements and disposable reorders for PRP, increased surgeon adoption and high conversion rates for PNS implants, and growing surgeon adoption and disposables growth for ultrasonics.

    04

    Enhanced Earnings Power and Operational Discipline

    Despite accelerating investments in growth drivers, BioVentus demonstrated enhanced earnings power, delivering an adjusted EBITDA margin of 23% in Q2, a 20 basis point expansion year-over-year. The company expects to maintain a full-year adjusted EBITDA margin of at least 20%. This is achieved by leveraging durable revenue growth, stable gross margins, and disciplined cost management across the business.

    05

    Strengthening Balance Sheet and Capital Allocation

    The company generated strong cash flow from operations, enabling an additional $24 million in debt repayment during Q2, bringing the year-to-date total to $46 million. This reduced net leverage to below 2x, with a target of below 1.5x by year-end. This deleveraging strategy aims to strengthen the financial position, drive further interest expense savings, and enhance future capital deployment optionality.

    06

    Segment-Specific Dynamics

    Surgical Solutions revenue declined 5% year-over-year but grew 5% sequentially, impacted by a $2 million timing shift of capital placements and international orders. Restorative Therapies saw a 2% decline due to a shift in Medicare patient mix, though growth is expected to resume. International revenue was down 1% (2% constant currency) due to distributor order timing, but strong double-digit growth is anticipated in the second half.

    AI-generated summary of the company’s earnings call. Not investment advice.